CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Boutique shopping is 'in vogue'
August 20, 2026
Tessa Clark, DAAP alum and fashion designer, owns Idlewild, an OTR shop recently featured in both the New York Times and Vogue.
CCM shares 2026-27 calendar of ticketed + free performances and events
August 20, 2026
Experience world-class performances by the next generation of performing and media artists at the University of Cincinnati College-Conservatory of Music (CCM). With more than 130 different performances and events, there is something happening nearly every week of the school year!
UC student veterans explore engineering careers
August 19, 2026
Stars and Stripes magazine highlighted the co-op experience of a University of Cincinnati mechanical engineering student who is working with the U.S. Army Corps of Engineers.